Welcome to Aescap
Investing in listed biotech companies with exceptional growth potential
The biotech sector is one of the most promising and innovative industries of our time. Our funds are designed to invest in highly innovative publicly traded biotech and life sciences companies.
Biotech companies focusing on innovative treatments for the more than 10.000 diseases for which no effective medicines yet exist are well placed to generate exceptional returns. These diseases include Alzheimer’s, osteoarthritis, infectious diseases, Parkinson’s, multiple sclerosis (MS), cardiovascular disease, and cancer.
Our investment team selects the most promising undervalued companies for the Aescap Life Sciences fund and the Aescap Genetics Fund based on fundamental analysis and intensive interaction with management. Our team members are highly experienced, have an excellent track record, and also invest significantly in the Aescap funds themselves. The funds’ AIFM is supervised by the AFM and DNB.
The name Aescap is derived from ‘Aesculapius’, the Roman god of medicine, and ‘capital’.
Biotech positioned for long-term growth
- Aging population creates explosive demand
- AI is transforming medicine development
- 2 billion new users from emerging markets
Why Aescap
- Proven track record. Our portfolio manager, Patrick Krol, and his team of highly experienced professionals with diverse backgrounds in biotech include an investment manager, analysts, a board advisor, portfolio advisors, and medical experts. This multidisciplinary approach enables us to make well-informed investment decisions.
- Skin in the game. Investment team members have invested over € 25 million in the Aescap funds. Demonstrating our strong commitment to and confidence in the funds.
- Heavily involved with portfolio companies. Aescap acts as a private equity investor on the stock exchange. Where necessary, we are not afraid to adopt an activist approach.
- Solid structure. Our investment team is overseen by a risk and compliance manager, as well as by various external parties such as the Netherlands Authority for the Financial Markets (AFM) and Apex Depositary Services.
Subscribe to our newsletter
Double return
At Aescap, we invest in listed biotech companies with exceptional growth potential. Companies pioneering the future of medicine. Our mission is to deliver excellent returns while making a significant impact on global health.
That’s why both the Aescap Life Sciences fund and the Aescap Genetics fund are classified under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR).
Investment strategy
- Next-generation medicine
- Outstanding management
- High-growth companies
- Diversification within our focus
- Undervalued companies
- Buy and Sell discipline
Update via webcast
Aescap regularly organizes webcasts to inform existing and potential investors about developments in our 2 funds and the portfolio companies. The next webcast will take place on 28 August at 3 p.m.
Interested in investing with Aescap? Contact us today to arrange an exploratory meeting: call us on 020 570 2940 or send an email.
Latest news
5 game changing products from the Aescap portfolio
Innovation in medicine R&D is gearing up rapidly, with over 20 new technologies being added over the years and AI improving timelines, costs, and success rate. We picked some eye-opening products from our portfolio companies that have been launched recently or delivered great results in clinical trials Sickle cell disease Crispr Therapeutics recently launched the
Intra-Cellular Therapeutics acquired by Johnson & Johnson
J&J is acquiring this Aescap Life Sciences portfolio company for $132 per share. This represents a 39% premium to Friday’s closing price of $ 94,87. The deal is valued at $ 14,6 billion. A 39% premium may not seem like much. However, there was already some takeover speculation in the share price, which rose earlier
Portfolio company Uniqure up 110%
Following positive feedback from the FDA around a potential approval of its treatment of Huntington’s disease, the share price of Uniqure rose by 110% yesterday. This large increase in the share price is not a surprise. There is no treatment available for this severe disease which causes nerve cells in the brain to gradually die.